NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Aakha Biologics

Aakha Biologics

Private
Frisco, TexasHealthcare & Life Scienceshttps://www.aakha.bio/

Last Round

Debt

Jul 23, 2024

Total Funding Raised

$3.7M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Aakha Biologics is a biotechnology company that develops next-generation multi-specific antibody immunotherapies for the treatment of cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologyantibody engineeringbispecific antibodydrug discoverybiotechmulti-specific antibodysolid tumor therapypreclinical drug developmentnatural killer cellsNK cell therapybiopharma licensingtherapeutic candidateIND-enabling studiesbiologics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aakha Biologics Comparables

Compare Aakha Biologics with similar companies based on industry and business-model similarity.

Aakha Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ypsilon Therapeutics
83%
Cantai Therapeutics
82%
Cullinan Oncology
76%

Aakha Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJul 23, 2024
SeedJul 17, 2024
GrantMay 22, 2024
AcceleratorMay 1, 2021

Key People

Founding team and executive leadership

Hemanta Baruah

Founder & CEO of Aakha Biologics

Founding Team

Aakha Biologics Investors

Notable investors and investment history

Aakha Biologics investors
InvestorRounds
National Cancer InstituteGrant
Opus8Seed
82VSAccelerator
Cancer Prevention and Research Institute of TexasGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 2, 2026

    Grew 60% QoQ from 5 to 8 employees.

  • May 1, 2021

    Raised an accelerator round with 82VS and Alloy Therapeutics.

Aakha Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aakha Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aakha Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersFrisco, Texas
Employee Range8
Year Founded2021
Last FundingJul 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.